Oncotelic Therapeutics Inc. has presented new data demonstrating the capabilities of its Deciparticle platform, a scalable nanotechnology system designed to transform drug delivery in immunology and oncology. The platform's ability to package water-resistant drugs into uniform nanoparticles small enough for intravenous administration represents a significant advancement in nanomedicine delivery systems.
Recent data presented at the 2025 San Antonio Breast Cancer Symposium revealed that the Deciparticle platform successfully packaged all five main macrolide mTOR inhibitors, including temsirolimus, sirolimus, ridaforolimus, Everolimus (Afinitor), and umirolimus, into stable, monodisperse particles. This compatibility across multiple therapeutic categories suggests the platform could streamline treatment protocols for various cancer types. The platform also demonstrated effectiveness with tacrolimus, forming stable nanoparticles with diameters of less than 20 nanometers, highlighting its ability to handle diverse drug structures.
The technology's versatility extends to complex peptides, with successful packaging of both linear and cyclic peptides including exenatide and cyclosporine A. This capability addresses a significant challenge in drug delivery, as many therapeutic peptides have traditionally been difficult to administer effectively due to stability and delivery issues. The platform's clinical-stage nanomedicine, Sapu Nano, serves as the foundation for these advancements.
For investors and industry observers seeking additional information, the company maintains a newsroom at https://ibn.fm/OTLC where updates are regularly posted. The broader implications of this technology extend beyond Oncotelic's immediate pipeline, potentially influencing how pharmaceutical companies approach drug formulation and delivery across multiple therapeutic areas.
The Deciparticle platform's ability to create uniform nanoparticles from challenging compounds could lead to improved drug efficacy, reduced side effects, and expanded treatment options for patients with difficult-to-treat cancers and immunological conditions. As the platform continues to demonstrate compatibility with various drug classes, it may enable more targeted and efficient delivery of existing therapeutics while opening new possibilities for drug development. The technology represents a convergence of nanotechnology and pharmaceutical science that could reshape treatment paradigms in coming years, particularly for conditions where current delivery methods limit therapeutic effectiveness.
